Suscribirse

Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness - 14/04/20

Doi : 10.1016/j.jaad.2019.10.079 
Nour Kibbi, MD, Yuemei Zhang, MD, MBA, David J. Leffell, MD, Sean R. Christensen, MD, PhD ⁎
 Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 

∗Correspondence to: Sean R. Christensen, MD, PhD, Yale Dermatologic Surgery, 40 Temple Street, Suite 5A, New Haven, CT 06510.Yale Dermatologic Surgery40 Temple Street, Suite 5ANew HavenCT06510

Abstract

Background

Photodynamic therapy (PDT) has been reported as a treatment for cutaneous squamous cell carcinoma in situ (SCCis), but only limited data are available on the effectiveness of PDT with aminolevulinic acid (ALA-PDT).

Objective

To review the outcomes of SCCis treated with ALA-PDT and examine factors associated with response.

Methods

A retrospective review identified 58 patients with 68 primary SCCis lesions treated with ALA-PDT and blue light illumination. Patient demographics, lesion features, treatment details, clinical response, and subsequent recurrence were extracted from medical record reviews.

Results

On completion of PDT the initial complete response rate was 77.9% and was not associated with the number of PDT treatments. On multivariate analysis factors associated with response were location on the face, tumor diameter <2 cm, and longer ALA incubation time. Lesions treated with a maximum incubation time of <3 hours had a 53.3% response compared with 84.9% for longer incubation. Subsequent recurrence of SCCis was noted in 7 of 53 cases (13.2%) at a median time of 11.7 months.

Limitations

This was a retrospective study performed at a single institution without systematic follow-up.

Conclusions

ALA-PDT may be an effective treatment for selected cases of SCCis. Effectiveness is impacted by anatomic location, tumor diameter, and ALA incubation time.

El texto completo de este artículo está disponible en PDF.

Key words : aminolevulinic acid, Bowen disease, humans, photodynamic therapy, retrospective studies, skin neoplasms, squamous cell carcinoma in situ, treatment outcome

Abbreviations used : ALA, ALA-PDT, CR, PDT, SCCis


Esquema


 Funding sources: Supported by a Career Development Award from the Dermatology Foundation (Dr Christensen).
 Conflicts of interest: None disclosed.
 IRB approval status: Reviewed and approved by the Yale Institutional Review Board (IRB number 2000024076).
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 82 - N° 5

P. 1124-1130 - mai 2020 Regresar al número
Artículo precedente Artículo precedente
  • Racial differences in dermatologic conditions associated with HIV: A cross-sectional study of 4679 patients in an urban tertiary care center
  • Alexandra M. Bender, Olive Tang, Raveena Khanna, Sonja Ständer, Sewon Kang, Shawn G. Kwatra
| Artículo siguiente Artículo siguiente
  • Bidirectional association between alopecia areata and major depressive disorder among probands and unaffected siblings: A nationwide population-based study
  • Ying-Xiu Dai, Ying-Hsuan Tai, Chih-Chiang Chen, Yun-Ting Chang, Tzeng-Ji Chen, Mu-Hong Chen

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.